Transcatheter aortic valve replacement in bicuspid aortic valve disease

Kochman, Janusz; Rymuza, Bartosz; Huczek, Zenon

doi:10.1097/hco.0000000000000219

Cited by 17 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Namely, it should not be based solely on the annular but rather on supra-annular measurements taking into account the intracommissural distance. The observed device undersizing in our registry suggests that operators applied this new strategy [29]. It should also be taken into account that the new-generation valves are equipped with sealing cuff that could further overcome the previously observed drawbacks of undersizing.…”

Section: Discussionmentioning

confidence: 79%

Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background The aim of this study was to evaluate the outcomes of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BiAV) stenosis using a mechanically expanded Lotus™ device. The prior experience with first-generation devices showed disappointing results mainly due to increased prevalence of aortic regurgitation (AR) that exceeded those observed in tricuspid stenosis. Methods and results We collected baseline, in-hospital, 30-day and 2-year follow-up data from a prospective, multicentre registry of patients with BiAV undergoing TAVI using Lotus™ valve. Safety and efficacy endpoints were assessed according to VARC-2 criteria. The study group comprised 24 patients. The mean age was 73.5 years and the mean EuroSCORE 2 was 4.35 ± 2.56%. MDCT analysis revealed Type 1 BiAV in 75% of patients. The mean gradient decreased from 60.1 ± 18.3 to 15 ± 6.4 mm Hg, the AVA increased from 0.6 ± 0.19 to 1.7 ± 0.21 cm 2. One in-hospital death was observed secondary to aortic perforation. There was no severe AR and the rate of moderate AR equalled 9% at 30 days (n = 2). Device success was achieved in 83% and the 30-day safety endpoint was 17%. In the 2-year follow-up, the overall mortality was 12.5% and the 2-year composite clinical efficacy endpoint was met in 25% of the patients (n = 6) Conclusions The TAVI in selected BiAV patients using the Lotus™ is feasible and characterized by encouraging valve performance and mid-term clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 79%

Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The best method for valve sizing in BAV has yet to be defined. The usual perimeter/area at the annulus is still the mainstay way for sizing, but there have been reports and presentations taking structures above the annulus into account for sizing purposes . The practice usually recommended a smaller valve size than annular measurements.…”

Section: Methodsmentioning

confidence: 99%

Permanent pacemaker implantation after transcatheter aortic valve replacement in bicuspid aortic valve patients

Xiong

Liao

et al. 2018

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…27 For instance, several institutions have published observational studies that proclaim the feasibility and safety of performing TAVR for bicuspid AS. [28][29][30] However, there have been no large-scale, randomized control trials designed specifically for this congenital patient As the indications for TAVR have expanded over time (Figure 2…”

Section: Expanding Indicationsmentioning

confidence: 99%

A Decade Later, Continued Transformation of Transcatheter Aortic Valve Replacement

Young¹,

Elmariah²

2018

US Cardiology Review

View full text Add to dashboard Cite

The emergence of transcatheter aortic valve replacement as an effective treatment option in appropriately selected patients with severe aortic valve stenosis has proven to be revolutionary to the fields of interventional cardiology and cardiac surgery. As percutaneous technologies continue to mature and indications for transcatheter valve therapy concurrently expand, the contemporary management of valvular heart disease necessitates a multidisciplinary heart team approach that considers the indication, multimodality imaging, anesthetic and procedural strategy, and selection of the appropriate valve prosthesis for each patient. We provide an overview of the historical development of transcatheter aortic valve replacement, commercially available and investigative devices, landmark clinical trial data, and developments on the horizon that aim to further advance the care of patients with aortic valve disease.

show abstract

Transcatheter aortic valve replacement in bicuspid aortic valve disease

Abstract: The existing literature supports the use of TAVR in selected high-risk BiAV patients, although the final role of this technique in this cohort of patients can only be established once a larger, preferably randomized, study comparing TAVR with surgery is performed.

Cited by 17 publications

References 30 publications

Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry

Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis utilizing the next-generation fully retrievable and repositionable valve system: mid-term results from a prospective multicentre registry

Permanent pacemaker implantation after transcatheter aortic valve replacement in bicuspid aortic valve patients

A Decade Later, Continued Transformation of Transcatheter Aortic Valve Replacement

Contact Info

Product

Resources

About